Policy & Regulation
Opsidio doses first subject in OpSCF Phase 2a clinical trial
30 November 2023 -

Opsidio, LLC, a US-based clinical stage biotechnology company, announced on Wednesday that it has dosed its first subject in the Phase 2a clinical trial of OpSCF, the company's pioneering monoclonal antibody against stem cell factor, in subjects suffering from moderate to severe atopic dermatitis.

The company is collaborating with AbbVie for the development of OpSCF.

The study, a randomised, double-blind, placebo-controlled, Phase 2a study, is to assess the efficacy and safety of OpSCF in the treatment of adults with moderate to severe atopic dermatitis. The primary endpoint is the percent change in the Eczema Area and Severity Index (EASI) score from baseline, at week 16, while the secondary endpoint comprises safety and tolerability and improvement in pruritus, body surface area, and quality of life.